Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||Bemcentinib + Erlotinib|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Bemcentinib||BGB 324|BGB-324|BGB324|R428|R-428||AXL Inhibitor 29||Bemcentinib (BGB-324) is a small molecule inhibitor of Axl, which inhibits tumor growth and may overcome EMT-mediated acquired drug resistance (PMID: 20145120, PMID: 31134766).|
|Erlotinib||Tarceva||CP358774||EGFR Inhibitor (Pan) 58 EGFR Inhibitor 1st gen 3||Tarceva (erlotinib) is a first-generation EGFR inhibitor that blocks EGFR signaling, potentially leading to inhibition of tumor growth (PMID: 30069756). Tarceva (erlotinib) is FDA approved for use in patients with non-small cell lung cancer harboring EGFR exon 19 deletions and/or EGFR L858R, and in combination with gemcitabine for patients with locally advanced, unresectable, or metastatic pancreatic cancer (FDA.gov).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|AXL over exp||head and neck cancer||sensitive||Bemcentinib + Erlotinib||Preclinical||Actionable||In a preclinical study, Bemcentinib (BGB-324) reverted acquired Tarceva (erlotinib)-resistance in head and neck cancer cell lines over expressing Axl and inhibited cell growth in culture (PMID: 24026012).||24026012|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT02424617||Phase Ib/II||Bemcentinib + Erlotinib||A Study of BGB324 in Combination With Erlotinib in Patients With Non-Small Cell Lung Cancer||Completed||USA||0|